In the context of pancreatic cancer, approximately 60% of SMAD4 mutations exhibit loss of heterozygosity, and about 50% involve homozygous deletions or intragenic inactivating mutations [14]. The gene discussed is SMAD4; the disease is familial pancreatic carcinoma.